Compare Atmos Energy Corporation (ATO) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Cytokinetics Inc — how do they compare? Atmos Energy Corporation trades at $168.76 (market cap $28.38B), while Cytokinetics Inc trades at $76.66 (market cap $10.78B). The key difference: Atmos Energy Corporation is far larger — about 2.6× Cytokinetics Inc's market cap, and Atmos Energy Corporation pays a 2.38% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| ATO | CYTK | |
|---|---|---|
Market Cap | $28.38B | $10.78B |
Sector | Utilities | Technology |
52-Week High | $192.25 | $87.26 |
52-Week Low | $162.44 | $34.31 |
Enterprise Value | $38.18B | $10.88B |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $170.19, down 1.04% today, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $1.43, beating expectations by 5.9%, and maintains strong fundamentals with 28.5% net income margin and $4.70B revenue. Recent board appointments and dividend declarations highlight corporate stability, while analyst consensus targets $190.57 with 45% buy ratings.
ATO presents a mixed outlook with solid earnings growth and dividend stability offset by bearish technical indicators and negative cash flow trends. The stock offers value through consistent profitability and infrastructure investments, though investors face risks from high capital expenditures and debt levels that could pressure future returns.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
